In order to overcome the unsatisfactory situation of HER2‐targeted therapy, timely evaluation of gene alterations along with the treatment progresses is of great importance so as to aid in better therapeutic management and clinical decision‐making for GC patients. Here, ERBB2 is linked to gastric cancer.